Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
These findings provide insights into the optimal use of anti-CD38 mAbs in patients with RRMM who are transplant-ineligible and aged ≥65 years and on candidates who are appropriate for novel approaches, such as chimeric antigen receptor T-cell or bispecific T-cell engager therapy.
Authors
- Hiroto Jojima
- Koichi Osaki (ORCID: https://orcid.org/0000-0002-2051-9980)
- Nao Yoshida‐Sakai (ORCID: https://orcid.org/0000-0001-8375-3662)
- Takashi Okamura (ORCID: https://orcid.org/0000-0001-8245-3318)
- Satoshi Yamasaki (ORCID: https://orcid.org/0000-0002-6143-7906)
- Yutaka Imamura (ORCID: https://orcid.org/0000-0003-4296-3457)
- Michitoshi Hashiguchi
Institutions
- St Mary's Hospital (JP)
Publication Details
- Journal
- Hematology Reports
- Published
- 2024-11-18
- DOI
- https://doi.org/10.3390/hematolrep16040068
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00